ArticleGeroScience2026
Targeting cellular senescence mitigates chemotherapy-induced bone loss in young and aged mice.
Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Chemotherapy-induced bone loss represents a major clinical challenge, particularly in aging populations, yet the contribution of cellular senescence to this process and its therapeutic potential remain incompletely understood. Here, we investigated the role of chemotherapy-induced cellular senescence in mediating skeletal deterioration following chemotherapy and evaluated the therapeutic potential of senolytic treatment. Young (3-month-old) and aged (20-month-old) male and female mice were treated with doxorubicin (DX), a chemotherapeutic agent, dasatinib/quercetin (DQ), senolytic agents, or their combination (DX/DQ). Chemotherapy-induced hallmark features of accelerated skeletal aging, including trabecular bone loss, increased marrow adiposity, and upregulation of senescence-associated and inflammatory gene expression. These effects were sex- and age-dependent and were more pronounced in females. Senolytic treatment with DQ partially restored osteogenic gene expression, including Alpl, Runx2, and Dmp1, and reduced marrow adiposity, particularly in aged females, indicating preservation of bone marrow niche function. Proteomic analysis of cortical bone revealed that DX-induced cellular senescence was associated with extracellular matrix remodeling and a metabolic shift toward glycolysis, characterized by increased inflammatory collagen isoforms and glycolytic enzymes. DQ treatment partially reversed these molecular signatures, including restoration of several extracellular matrix proteins associated with bone architecture and mineralization. Despite these molecular improvements, recovery of trabecular bone architecture remained modest, suggesting that senolytic-mediated molecular remodeling precedes detectable skeletal recovery. Collectively, these findings support a model in which chemotherapy-induced bone loss is driven by both early osteoblast suppression and senescence-driven microenvironmental dysfunction, identifying cellular senescence as a potential therapeutic target for preserving skeletal health following chemotherapy.
Indexed as
Identifiers
42686970What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.